Loading
Dual immunotherapy with nivolumab and ipilimumab lengthened survival compared with sunitinib in intermediate- and poor-risk advanced kidney cancer, with about one in ten patients achieving a complete response that has proved durable over years.
Phase 3 trial of 1,096 patients with untreated advanced clear cell renal cell carcinoma randomised to nivolumab plus ipilimumab (four doses) followed by nivolumab, or sunitinib, with co-primary endpoints in intermediate- and poor-risk patients.
In intermediate and poor risk, 18-month overall survival was 75 versus 60 percent (hazard ratio 0.63), response 42 versus 27 percent and complete response 9 versus 1 percent; favourable-risk patients had higher response to sunitinib at first analysis. Long-term follow-up shows sustained survival benefit.
Nivolumab-ipilimumab is a first-line standard for intermediate- and poor-risk clear cell kidney cancer, notable for durable complete responses and treatment-free intervals.
Shares CheckMate 214, Ipilimumab, Nivolumab.
Shares Clear cell renal cell carcinoma, Sunitinib, New England Journal of Medicine.
Shares Sunitinib, New England Journal of Medicine.
Shares Clear cell renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Nivolumab, New England Journal of Medicine.
Shares CheckMate 214, Ipilimumab, Nivolumab.
Shares Clear cell renal cell carcinoma, Sunitinib.
Shares Ipilimumab, Nivolumab.